Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer

Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. However, drug-induced interstitial lung disease (ILD) is recognized as a serious adverse event associated with EGFR-tyrosine kinase inhibitors (TKIs). We herein report a 78-year-old w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Internal Medicine 2021/02/15, Vol.60(4), pp.591-594
Hauptverfasser:	Nishima, Shunichi, Miyanaga, Akihiko, Saito, Sho, Yuasa, Mizuki, Takahashi, Satoshi, Kashiwada, Takeru, Sugano, Teppei, Noro, Rintaro, Minegishi, Yuji, Terasaki, Yasuhiro, Saito, Yoshinobu, Kubota, Kaoru, Seike, Masahiro, Gemma, Akihiko
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides Adenocarcinoma afatinib Afatinib - therapeutic use Aged Aniline Compounds Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Case Report drug-induced ILD Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - genetics Female Humans Internal medicine interstitial lung disease Lung cancer Lung diseases Lung Diseases, Interstitial - chemically induced Lung Diseases, Interstitial - drug therapy Lung Diseases, Interstitial - genetics Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutants Mutation Non-small cell lung carcinoma osimertinib Protein Kinase Inhibitors - adverse effects Protein-tyrosine kinase
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!